This study will test if a new eye drop, KPI-012, is safe and works well for people with PCED (Persistent Corneal Epithelial Defect). About 90 people with PCED, which is a stubborn eye problem, will join the study in the USA. PCED can be caused by conditions like diabetes, dry eyes, or eye injuries. A first group will try the high-strength drops to check safety, then others will be randomly chosen to get either KPI-012 or a placebo (a fake treatment) for 8 weeks. The study will last about 34 weeks in total.
Key points:
- Study lasts around 34 weeks, including 8 weeks of treatment.
- Participants must have had PCED for at least 7 days due to specific conditions.
- People with active eye infections, recent eye surgeries, or certain medical histories cannot join.
Participants need to suspend some medications and treatments, like contact lenses and Botox, during the study. This study aims to find out if the new treatment can help heal the eye better than no treatment.
How understandable was the trial content above?
Hard to understand
Easy to understand